泌尿外科

订阅

MedSci主页 / 所有栏目 / 泌尿外科

Clinica Chimica Acta：阿尔及利亚人群年龄相关前列腺特异抗原(PSA)参考值的建立

2020-06-24 MedSci原创 MedSci原创

前列腺特异抗原(PSA);参考值
关注

设置前列腺特异性抗原(PSA)的年龄和种族相关参考限(Rls)有助于提高其作为前列腺癌(PCa)筛查工具的诊断准确性。但是，由于金标准程序的费用较高，临床实验室很少能建立这一程序。

设置前列腺特异性抗原(PSA)的年龄和种族相关参考限(Rls)有助于提高其作为前列腺癌(PCa)筛查工具的诊断准确性。但是，由于金标准程序的费用较高，临床实验室很少能建立这一程序。本研究使用了另一种方法来生成特定RIs。

研究人员从实验室信息系统中检索了4年多的实验室结果(总PSA结果1491个，游离PSA结果989个)。并采用了包含/排除过程。采用混合数据集的Hoffmann、Bhattacharya和最大似然法进行年龄相关第95百分位数的估计，采用截断数据集的分位数回归和限制性三次样条模型进行估计。为了验证这些与年龄相关的RIs，对PSA (%fPSA) 26.4%阳性的游离PSA (%fPSA)作为前列腺癌替代物的百分比进行了一致性分析。

采用Hoffmann、Bhattacharya、maximum likelihood和quantile regression方法对40 - 49岁男性的PSA分别为3.0、2.6、2.3和2.8 ng/mL；50 - 59岁男性分别为4.1、3.3、2.8和3.2 ng/mL；60-69岁男性5.6、4.2、3.4、3.5 ng/mL；70-79岁男性7.5、5.4、4.1和3.9 ng/mL。年龄相关的Rls如Bhattacharya、maximum likelihood和quantile regression反映了更好的% fPSA阳性。

研究结果表明，年龄相关的总PSA参考限可以通过使用分位数回归模型或Bhattacharya和最大似然法对实验室数据进行回顾性分析得出，然后再使用线性回归模型。

原始出处：

KhelilMohamed Mokhtar,Establishment of age-related prostate-specific antigen (PSA) reference limits in the Algerian population: A comparison of four indirect methods

 

 

 

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1933484, encodeId=8a9f193348405, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Thu May 13 06:20:33 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849949, encodeId=0ee1184994935, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Apr 24 20:20:33 CST 2021, time=2021-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271085, encodeId=5ec412e108542, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jun 26 13:20:33 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623379, encodeId=64e916233e9d4, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Jun 26 13:20:33 CST 2020, time=2020-06-26, status=1, ipAttribution=)]
    2021-05-13 lily1616

    #年龄相关#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1933484, encodeId=8a9f193348405, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Thu May 13 06:20:33 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849949, encodeId=0ee1184994935, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Apr 24 20:20:33 CST 2021, time=2021-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271085, encodeId=5ec412e108542, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jun 26 13:20:33 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623379, encodeId=64e916233e9d4, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Jun 26 13:20:33 CST 2020, time=2020-06-26, status=1, ipAttribution=)]
    2021-04-24 windight

    #CTA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1933484, encodeId=8a9f193348405, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Thu May 13 06:20:33 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849949, encodeId=0ee1184994935, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Apr 24 20:20:33 CST 2021, time=2021-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271085, encodeId=5ec412e108542, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jun 26 13:20:33 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623379, encodeId=64e916233e9d4, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Jun 26 13:20:33 CST 2020, time=2020-06-26, status=1, ipAttribution=)]
    2020-06-26 zhaozhouchifen

    #PSA#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1933484, encodeId=8a9f193348405, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Thu May 13 06:20:33 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849949, encodeId=0ee1184994935, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Apr 24 20:20:33 CST 2021, time=2021-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271085, encodeId=5ec412e108542, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jun 26 13:20:33 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623379, encodeId=64e916233e9d4, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Jun 26 13:20:33 CST 2020, time=2020-06-26, status=1, ipAttribution=)]
    2020-06-26 xiaoyeshuang

    #抗原#

    0